Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 8Terminated 5Recruiting 5Completed 5Withdrawn 3No longer available 1Available 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 2Plasma cell 2Tumor-Agnostic 1

Conditions

Neoplasms 2Multiple Myeloma 2Desmoid Tumors 2Paraproteinemias 1Neoplasms, Plasma Cell 1Hematologic Diseases 1Corneal Diseases 1Blood Protein Disorders 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × nirogacestat × Clear all
NCT05879146 2026-05-15

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Tumor-Agnostic

Neoplasms

NCT07176689 2026-05-08

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 4 Recruiting
50 enrolled
Sarcoma

Desmoid Tumors

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Regeneron Pharmaceuticals

Phase 1 Recruiting
317 enrolled
Plasma cell

Multiple Myeloma

NCT05949099 2025-09-08

Study of Cryoablation and Nirogacestat for Desmoid Tumor

Stanford University

Phase 2 Recruiting
28 enrolled
Sarcoma

Desmoid Tumors

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡